Insights

Insights From Our Experts

Articles

Case Study: Early-Stage Asset Valuation

The rewards of developing a new drug can be very attractive but they come with inherent risks. It is important to ensure that investment decisions on clinical development are made after examining the risk profile of…

How Artificial Intelligence Is Transforming Pharma

From drug discovery to clinical trials to commercialization, artificial intelligence (AI) and machine learning (ML) technologies are transforming the pharma and life sciences industries. Industry leaders who recognize the potential of AI and ML are now…

Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal

During a recent webinar panel, EVERSANA and Reuters gathered industry leaders to discuss the tough questions facing pharma, specifically in the wake of a new U.S. presidency. EVERSANA CEO Jim Lang; Joe Jimenez, Ex-Novartis CEO and…

Five Biggest Data Challenges for Life Sciences

Data is transforming the competitive landscape in life sciences. From the rise of personalized medicine and value-based healthcare to evolving commercial strategies, the effective utilization of data is critical to solving for better patient outcomes. There…

Approaching Clinical Pathway Development as an Art

Much like any artform, creating a clinical pathway requires forethought, innovative design and strategic execution in the hands of the physician — except in the art of healthcare, the most important critic is the patient. While…

Ensuring Speed, Scale and Certainty in Supply Chain

Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or…

Navigating the Cycle of Supply Chain Complexity

As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can…

Impact of COVID-19 on the Quadruple Aim

COVID-19 has transformed the practices of healthcare professionals as well as the patient journey, leaving lasting impacts on the Quadruple Aim — cost, patient experience, population health and healthcare provider (HCP)/staff support. As independent, private medical…

Managing Risks to Improve Health Outcomes: How to Move Population Health Forward in an Era of Uncertainty

At the Canadian Association for Population Therapeutics (CAPT) Annual Conference, Sumeet Singh, Senior Director, EVERSANA, delivered a presentation on pharmacoeconomic analysis and outcome-based agreements and what they mean for Canadian private payers. Watch his session below…

The Power of Working Together With the Rare Disease Community

“Alone, we can do so little; together, we can do so much.” – Helen Keller This sentiment addresses the power of working together to improve health in rare disease. At EVERSANA, we have developed a unique…